PDSB News and Press, PDS Biotechnology Corporation From 07/26/22

FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary V...

The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...

FLORHAM PARK, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary V...

The following slide deck was published by PDS Biotechnology Corporation in conjunction with this event. For further details see: pdsb

PDS Held A Conference Call Following ASCO Data Presentations. On June 7, PDS management held a conference call to discuss the full data from its presentations at the American Society for Clinical Oncology (ASCO) meeting on June 5 and 6. The presentations were from the Phase 2 VERSATILE-002 tri...

NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Tonix Pharmaceuticals (NASDAQ: TNXP), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PDS Biot...

Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...

Clinical-stage biotech, PDS Biotechnology (NASDAQ:PDSB) announced on Thursday that the U.S. Food and Drug Administration granted its Fast Track designation to its lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda for a certain type of head and neck cancer...

PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA ® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (N...

FLORHAM PARK, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Vers...